Literature DB >> 10810302

Overexpression of thyroid hormone receptor beta1 is associated with thyrotropin receptor gene expression and proliferation in a human thyroid carcinoma cell line.

S T Chen1, H Y Shieh, J D Lin, K S Chang, K H Lin.   

Abstract

To correlate the differentiation phenotype of two human thyroid cancer cell lines with their expression of various molecular markers, we analyzed the mRNA levels of four thyroid-specific genes, including thyrotropin receptor (TSHR), thyroglobulin (Tg), thyroid transcription factor-1 (TTF-1), and paired-box containing transcription factor-8 (PAX-8) genes. The results showed a differentiation-status-related pattern in which a well-differentiated cell line (WRO) expressed all the four genes, in contrast to an anaplastic cell line (ARO) that expressed TTF-1 and reduced levels of TSHR, but no Tg or PAX-8 genes. Furthermore, to verify the finding of concomitant loss of beta subtype thyroid hormone receptor (TRbeta) and TSHR gene expression in neoplastic thyroid tumors (Bronnegard et al. 1994), we examined the expression levels of TRbeta1 gene in these cell lines. Whereas the WRO cells produced an abundant amount of TRbeta1 protein detectable by immunoprecipitation, the ARO cells produced none. This new observation prompted us to investigate whether overexpression of TRbeta1 protein in ARO cells might produce changes in the differentiation phenotypes. We found that the level of expression of the TSHR gene and the proliferative index of ARO cells were significantly upregulated in the cells stably transfected with wild-type TRbeta1. These findings suggest that TRbeta1 protein overexpression can affect the differentiation phenotypes and induce more efficient cell proliferation of the anaplastic ARO cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810302     DOI: 10.1677/joe.0.1650379

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships.

Authors:  Leggy A Arnold; Aaron Kosinski; Eva Estébanez-Perpiñá; Robert J Fletterick; R Kiplin Guy
Journal:  J Med Chem       Date:  2007-10-05       Impact factor: 7.446

2.  Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.

Authors:  Shih-Che Hua; Tien-Chun Chang; Hau-Ren Chen; Chieh-Hsiang Lu; Yi-Wen Liu; Shu-Hsin Chen; Hui-I Yu; Yi-Ping Chang; Ying-Ray Lee
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

3.  Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.

Authors:  Szu-Tah Chen; Dah-Wel Liu; Jen-Der Lin; Fang-Wu Chen; Yu-Yao Huang; Brend Ray-Sea Hsu
Journal:  Clin Exp Metastasis       Date:  2011-11-01       Impact factor: 5.150

Review 4.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

5.  Localization and expression of thyroid hormone receptors normal and neoplastic human thyroid.

Authors:  A Crescenzi; M F Graziano; E Carosa; E Papini; N Rucci; F Nardi; P Trimboli; A Calvanese; E A Jannini; M D'Armiento
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

6.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Authors:  Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2008-08-19       Impact factor: 5.958

7.  Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.

Authors:  Idit Dotan; Philip J R Roche; Miltiadis Paliouras; Elliot J Mitmaker; Mark A Trifiro
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.